Effects of argatroban combined with Shuxuening injection on Hcy,VEGF,and sCD40L levels and clinical efficacy in patients with acute cerebral infarction
10.3969/j.issn.1009-0754.2025.07.013
- VernacularTitle:阿加曲班联合舒血宁治疗对急性脑梗死患者Hcy、VEGF和sCD40L水平的影响和临床疗效
- Author:
Qiang JIA
1
;
Li TIAN
Author Information
1. 075000 河北张家口,张家口市第一医院内科重症医学科
- Keywords:
Acute cerebral infarction;
Argatroban;
Shuxuening injection;
Motor function;
Neurological function
- From:
Journal of Navy Medicine
2025;46(7):710-715
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effects of argatroban combined with Shuxuening injection on homocysteine(Hcy),vascular endothelial growth factor(VEGF),and soluble CD40 ligand(sCD40L)levels,as well as its clinical efficacy in patients with acute cerebral infarction.Methods From June 2023 to March 2024,98 patients with acute cerebral infarction were randomly assigned to experimental group(n=49)or control group(n=49)using stratified random sampling method.The control group received standard symptomatic treatment along with argatroban injection,and the experimental group additionally received intravenous Shuxuening injection.The neurological function[(National Institute of Health stroke scale,NIHSS)and(modified Rankin scale,mRS)scores],motor function[(Fugl-Meyer assessment scale,FMA)score],coagulation function[(activated partial thromboplastin time,APTT),(prothrombin time,PT),(fibrinogen,FIB),D-dimer],hemorheology parameters[(plasma viscosity,PV),(erythrocyte aggregation index,EAI),(hematocrit,HCT),(erythrocyte sedimentation rate,ESR)],serum cytokines[(homocysteine,Hcy),(vascular endothelial growth factor,VEGF),(soluble CD40 ligand,sCD40L)],and adverse reactions(dizziness,nausea,vomiting,rash,loss of appetite,abdominal distension,thrombocytopenia,and intracranial hemorrhage)were compare between the two groups.Results There were no significant differences in the NIHSS score,FMA score,mRS score,APTT,PT,FIB,D-dimer,PV,EAI,HCT,ESR,Hcy,VEGF,or sCD40L between the two groups before treatment(P>0.05).After 2 weeks of treatment,the experimental group showed lower NIHSS score,mRS score,FIB,D-dimer,PV,EAI,HCT,ESR,Hcy,and sCD40L,and higher total effective rate,FMA score,APTT,PT and VEGF than the control group(P<0.05).The incidence of adverse reactions in the experimental group was lower than that in the control group,but the difference was not statistically significant(P>0.05).Conclusion Argatroban combined with Shuxuening injection can enhance motor function,reduce neurological damage,improve coagulation function and hemorheological parameters,regulate serum cytokine levels,offer good safety,and provide a new option for the treatment of acute cerebral infarction.
